ub-221
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2018 (NCT03632291)
Timeline
Indications
Studied for
Mechanism of action
- Immunoglobulin epsilon heavy chainINHIBITOR
Immunoglobulin epsilon heavy chain inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05298215 | Phase 2 | Oct 5, 2022 | United BioPharma |
| NCT04404023 | Phase 1 | Jun 30, 2020 | UBP Greater China (Shanghai) Co., Ltd |
| NCT04175704 | Phase 1 | Jan 30, 2020 | United BioPharma |
| NCT03632291 | Phase 1 | Nov 30, 2018 | United BioPharma |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| United BioPharma | For profit | 3 | 3 | 2 | 2018 |
| UBP Greater China (Shanghai) Co., Ltd | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1